IV Iron for Athletes: When Infusion Makes Sense
Table of Contents
Introduction
Iron deficiency is common in athletic populations, with higher rates observed in female athletes and endurance disciplines. It can impair performance, and iron repletion may improve outcomes in some iron-deficient athletes — particularly those with very low ferritin or frank anemia — though the magnitude of benefit varies considerably with baseline iron status and the presence of anemia [1][2]. As awareness of iron deficiency has grown in athletic communities, so has interest in intravenous (IV) iron infusions — marketed in some circles as a faster, more powerful alternative to oral iron, particularly in discussions around IV iron for athletes.
I’m often asked about iron infusions—how to get one, and whether it’s possible to receive one without a strong medical indication. Sometimes these questions come from athletes, but increasingly they come from patients experiencing fatigue or burnout.
IV iron for athletes is a legitimate medical intervention with a defined, narrow set of indications. It is not a performance hack, it is not risk-free, and it is not appropriate for most athletes who present with iron deficiency. I wrote this article to walk through the evidence for when IV iron is genuinely indicated, what the research actually shows about its performance benefits, and the clinically significant risks that too many athletes — and some clinicians — underestimate.
Why Oral Iron Still Matters Before IV Iron for Athletes
Oral iron supplementation is the appropriate first-line intervention for iron-deficient athletes, and it works in the majority of cases. A 2024 systematic review and meta-analysis of randomized controlled trials confirmed that oral supplementation successfully increases serum ferritin and improves hematological markers in iron-deficient athletes, supporting its continued role as primary therapy [3].
However, oral iron has meaningful limitations that make it unsuitable for a subset of patients. Oral iron is absorbed via the small intestine with bioavailability ranging from approximately 2–20% in iron-deficient individuals, falling substantially lower in those with inflammation or high training loads [4]. Exercise raises hepcidin — an iron-regulatory hormone — in the hours following training, which can suppress intestinal iron absorption and reduce the effectiveness of oral supplementation taken close to training sessions [5]. This is one reason that alternate-day dosing — which allows hepcidin to return toward baseline between doses — is increasingly favored over daily dosing in clinical practice [3].
Beyond absorption, unabsorbed iron in the gastrointestinal tract causes dose-dependent side effects. A meta-analysis of 43 trials encompassing 6,831 adult participants found that ferrous sulfate significantly increased the risk of gastrointestinal side effects compared to placebo, with constipation (12%), nausea (11%), and diarrhea (8%) among the most commonly reported symptoms [6]. GI adverse effects are consistently documented across oral iron formulations in the wider tolerability literature, and in athletes whose training already challenges the gastrointestinal tract, this tolerability problem is clinically significant and a common driver of non-adherence.
In practice, I see this frequently. Many of my patients report gastrointestinal side effects with oral iron, and for some, standard preparations are simply not tolerated. In these cases, I often recommend alternative formulations such as sucrosomial iron, which are available in Finland and tend to be better tolerated, although they are more expensive. I also encourage the use of dietary heme iron sources, such as red meat, although these alone are rarely sufficient in clinically significant deficiency.
The practical consequence is that a subset of athletes either cannot absorb adequate iron orally or cannot tolerate the dose required to correct a meaningful deficiency within a reasonable timeframe. This is often the point at which IV iron enters the conversation.
At the same time, I often find that patients view IV iron as a shortcut. I make it clear to my patients that it is not. While it can correct iron deficiency more rapidly, it does not address the underlying cause, and any benefit may be temporary if that cause is not identified and managed.
When IV Iron for Athletes Is Considered: Clinical Context and Variation
IV iron bypasses the gastrointestinal tract entirely, delivering iron directly into the bloodstream. This makes it highly effective when oral absorption is impaired or when correction is needed more rapidly than oral therapy allows.
Before listing the indications, one point deserves particular emphasis for athletes reading this: Finnish clinical practice generally applies the same medical criteria used in the general population, and low ferritin alone is not usually enough to justify IV iron. There are no athlete-specific thresholds that lower the bar for infusion, regardless of training load, the ferritin targets used in sports science literature, or competitive calendar pressures. This reflects a deliberately conservative approach, as described in a Finnish expert review published in a national medical journal (Potilaan Lääkärilehti) by hematologists from major university hospitals (Tampere University Hospital and Oulu University Hospital): in otherwise healthy individuals with low ferritin but no anemia, oral iron is the appropriate treatment, and IV iron may be considered only exceptionally — particularly when ferritin is very low and oral treatment is not feasible or has clearly failed [7]. The same review explicitly warns that repeated IV iron on minimal indications can lead to harmful iron accumulation [7].
It is worth acknowledging that clinical practice varies internationally. Some sports medicine programs — particularly those working with elite national team athletes in other countries — use IV iron more liberally, with practitioners treating based on athlete-specific ferritin thresholds (for example, below 35–50 µg/L in distance runners) rather than general clinical cutoffs. This reflects a genuine tension between sports performance literature and population-based clinical guidelines.
In Finland, however, medical practice in this area remains conservative. IV iron is not routinely used on the basis of ferritin thresholds alone, and such an approach is generally not accepted in either publicly funded or private healthcare settings. Clinicians are expected to adhere to established indications, and deviating from these without clear medical justification may raise regulatory concerns.
Understanding where your own ferritin actually stands relative to both general and athlete-specific thresholds is therefore essential; for a detailed breakdown of how to interpret ferritin in an athletic context, see Ferritin Levels for Athletes: Reasons Why “Normal” Isn’t Optimal. From a Finnish clinical standpoint, however, athletes should not expect an infusion simply because their ferritin sits below the performance-optimal zone suggested by sports scientists.
When IV Iron Is Clinically Appropriate
The clinically accepted indications for IV iron — applicable to athletes and non-athletes alike — include the following. From a medical standpoint, there should be no distinction between an “athlete” and a “patient” when it comes to treatment thresholds; the same clinical criteria apply.
Failure of optimized oral therapy. If a patient has genuinely tried an adequately dosed oral iron regimen — typically 6–8 weeks, adjusted for tolerability and timing — with inadequate ferritin response and persistent symptoms, IV iron is a reasonable next step [3]. Optimizing oral therapy first means trying alternate-day dosing, adjusting timing relative to meals and training, and if necessary switching formulations before escalating to IV [7].
Documented GI intolerance. If a patient cannot tolerate therapeutic doses of oral iron despite trying different preparations and timing strategies, switching to IV iron is medically justified [7].
Severe deficiency with compromised hemoglobin mass. In patients with frank iron deficiency anemia — where both iron stores and hemoglobin mass are compromised — IV iron can facilitate erythropoiesis and produce meaningful performance gains. Research in 27 highly trained distance runners demonstrated that IV iron supplementation effectively increased ferritin levels within weeks and, in the subgroup with the lowest baseline iron status, produced measurable improvements in VO₂max of 3.3% and run time to exhaustion of 9.3% [8]. These gains were confined to the most severely depleted athletes, not the group as a whole.
Malabsorption conditions. Celiac disease, inflammatory bowel disease, or prior bariatric surgery all impair intestinal iron absorption sufficiently that IV iron is often the appropriate first choice [7].
Time-critical clinical need. IV iron is appropriate when correction is urgent — pre-operatively, for example [7].
So, as we can see, according to Finnish public healthcare criteria, IV iron may be considered even in the absence of anemia—but not without clearly low ferritin—and this remains an exception rather than standard practice.
It is also worth noting that, in practice, these criteria often require careful interpretation. Patients may understandably attribute symptoms to gastrointestinal intolerance or describe oral therapy as having “failed,” even when adherence has been inconsistent or dosing has not been optimal.
In my experience, there can also be a tendency—particularly in private practice settings—to frame symptoms or prior treatment responses in a way that supports escalation to IV therapy. This highlights the importance of careful clinical assessment to ensure that indications are genuine and clearly justified.
At the same time, IV iron should not be used in the absence of clear biochemical evidence of iron deficiency. Without demonstrably low ferritin, the rationale for treatment is difficult to justify—not only in Finland, where practice is conservative, but also in most evidence-based clinical settings internationally.
IV Iron for Athletes: Formulations and Clinical Differences
Modern IV iron preparations consist of a ferric hydroxide core within a carbohydrate shell that stabilizes the complex and controls iron release. The composition of that shell differs by formulation, producing clinically meaningful differences in dosing capacity, infusion time, safety profile, and cost [9].
The most commonly used modern formulations are:
Ferric carboxymaltose (FCM, Ferinject/Injectafer) allows up to 1,000 mg in a single 15-minute infusion. It is non-dextran with a low anaphylaxis risk. However, FCM is consistently associated with a substantially higher rate of hypophosphatemia than several other IV iron formulations — a risk that is particularly relevant for athletes, discussed in detail below [15].
Ferinject is one of the most widely used and best-known IV iron formulations in Finland, and it is commonly used in university hospital settings, as well as increasingly in private healthcare. It is also the formulation I most commonly prescribe in my own clinical practice.
Ferric derisomaltose (iron isomaltoside, Monoferric) allows high single-dose administration (typically around 1,000 mg, with higher doses possible depending on body weight) and is associated with a substantially lower risk of hypophosphatemia than ferric carboxymaltose[15].
Iron sucrose (Venofer) requires multiple infusions to achieve full repletion, as only relatively small amounts can be administered per session (commonly around 200 mg in clinical practice), meaning multiple clinic visits. It has a well-established safety profile, a low risk of hypersensitivity reactions, and a low risk of hypophosphatemia. It is also generally among the lower-cost IV iron options per dose [9].
Iron dextran is effective but is associated with higher rates of hypersensitivity reactions than non-dextran formulations [10].
Protocols for athletes do not differ from general medical practice. Dosing is calculated based on body weight, target hemoglobin, and current iron status, and all infusions are administered in a clinical setting with appropriate monitoring. In practice, at least in Finland, ferric carboxymaltose (Ferinject) is most commonly administered as a single dose of either 500 mg or 1,000 mg, depending on the severity of iron deficiency.
What the Evidence Actually Shows About Performance
Both athletes and patients more broadly often have high expectations regarding the effects of IV iron. In reality, however, these expectations frequently exceed the measurable physiological or performance benefits.
IV iron reliably and rapidly restores iron stores. Ferritin typically rises earlier than with oral iron, while hemoglobin response unfolds over subsequent weeks as the bone marrow incorporates newly available iron [8]. In athletes with severely compromised iron status — particularly those with frank anemia — IV iron can facilitate erythropoiesis and produce meaningful improvements in aerobic capacity, as the Garvican data above demonstrate.
However, IV iron does not reliably improve performance in athletes who are not anemic. A study of 15 national and international standard runners classified as iron-deficient non-anemic found that a single 500 mg IV iron injection significantly improved ferritin, serum iron, and transferrin saturation for at least 4 weeks — but did not lead to improved aerobic capacity in exercise tests to exhaustion [11]. For a broader discussion of what the full iron panel actually measures in athletes — including the distinction between serum iron, ferritin, transferrin saturation, and sTfR — see Serum Iron vs Ferritin: Which Test Actually Matters for Athletes? and Soluble Transferrin Receptor in Athletes: sTfR as the Advanced Iron Marker.
A separate randomized controlled trial involving 14 distance runners with clinically normal ferritin levels (30–100 µg/L) who received IV ferric carboxymaltose over 4 weeks found that serum ferritin increased substantially and perceived fatigue and mood disturbance improved. However, hemoglobin mass and 3,000 m time trial performance did not change significantly [12]. This is an important finding: ferritin can rise dramatically after IV iron, and an athlete may genuinely feel better, but this does not necessarily translate to measurable performance improvement.
A systematic review of 12 studies covering 283 athletes found that iron supplementation in non-anemic, iron-deficient athletes produced mixed results, with performance improvements observed in some studies but not others, and the most consistent benefits seen in athletes with the lowest baseline ferritin [13]. The equivocal nature of the evidence across the literature makes IV iron a treatment for confirmed, clinically significant deficiency — not a general ergogenic intervention.
In my experience, expectations also play an important role in how patients perceive the effects of IV iron. When expectations are high, and the treatment itself is perceived as more intensive or “powerful” than oral therapy, the subjective response can be amplified.
This does not mean that the benefit is purely placebo—there may well be a genuine physiological effect—but expectation and context likely contribute to how strongly patients feel the improvement. As a result, patients may report noticeable changes even when objective measures, such as performance or hemoglobin mass, remain unchanged.
This gap between subjective experience and measurable outcomes can contribute to strong word-of-mouth narratives around IV iron, which in turn may shape expectations in other patients and influence demand in clinical practice.
The Recovery Timeline: Faster Than Oral, But Not Instant
Athletes are often told IV iron is a “quick fix,” which is partially accurate and partially misleading. Ferritin rises faster than with oral iron, but hemoglobin production unfolds over subsequent weeks, and full hematologic recovery in severely deficient athletes takes months, not days [8][12].
As a practical matter, iron studies should generally not be re-checked until approximately 4 weeks post-infusion, since circulating iron in the immediate post-infusion period can artificially inflate ferritin readings and interfere with assay accuracy [9]. This mirrors the same interpretive caution that applies in any context of acute physiological stress — a point covered in depth in Post-Marathon Blood Work: Understanding Your Blood Test After a Marathon and When Results Return to Normal. It is also worth noting that ferritin is an acute-phase reactant: if an athlete has a minor illness or has recently completed an intense event around the time of re-testing, ferritin may be transiently elevated for reasons unrelated to iron stores.
Compared to oral supplementation — which requires 6–8 weeks to produce meaningful changes in stores at therapeutic doses [3] — IV iron offers a genuine speed advantage for restoring ferritin. But that advantage is only clinically meaningful for the athlete who meets the criteria for IV iron in the first place.
I often explain to my patients that any noticeable improvement typically occurs over the course of weeks, while the physiological effects can last for several months. Iron levels also tend to decline gradually over time rather than immediately. In practice, many patients report being satisfied with the outcome for a year or longer, although this depends on the underlying cause of the deficiency and whether it has been addressed.
However, as I mentioned earlier, IV iron is not a long-term solution. Over time, many patients return for reassessment and often request repeat iron testing. In some cases—particularly when the underlying cause persists and clinical criteria are met—treatment may need to be repeated at intervals, commonly on the order of one to two years.
A more sustainable long-term approach would be to address iron deficiency through appropriate supplementation and dietary sources of heme iron. IV iron is not without risk, as we will discuss next.
Risks: The Conversation Athletes Are Not Having
This section matters most. IV iron is not a supplement — it is a medical intervention administered intravenously, and it carries distinct risks that athletes asking for an infusion may not have fully considered.
Hypersensitivity and anaphylaxis. All IV iron formulations carry a risk of hypersensitivity reactions. Modern formulations are substantially safer than older high-molecular-weight iron dextran preparations, but the risk is not zero. A retrospective cohort study found anaphylaxis rates per 10,000 first administrations of approximately 9.8 for iron dextran and 4.0 for ferumoxytol, with lower rates for newer non-dextran formulations such as FCM and iron sucrose [10]. Acute hypersensitivity reactions require immediate clinical management including epinephrine, and all IV iron infusions must be administered in settings equipped to handle anaphylaxis [10]. The Finnish medicines agency Fimea received 62 adverse event reports related to iron infusions over a three-year period, of which 34 were classified as serious and 22 of those as severe hypersensitivity reactions — underscoring that IV iron must always be administered with full resuscitation readiness [7].
In clinical practice, anaphylaxis remains the most feared complication of IV iron administration. Although rare, it is potentially life-threatening and requires immediate recognition and management.
Particular caution is required in pregnant patients. Hypersensitivity reactions—including anaphylaxis—can have serious consequences for both the mother and fetus. I am aware of cases where severe reactions have led to urgent obstetric interventions, including emergency preterm cesarean section.
For this reason, IV iron in pregnancy should be administered in an appropriate clinical setting with full monitoring and resuscitation readiness, and only when clear diagnostic criteria are met.
Hypophosphatemia. This is the risk that most athletes — and many non-specialist clinicians — do not know about, and it is especially relevant in an athletic context. Ferric carboxymaltose (FCM) induces hypophosphatemia through a FGF23-mediated mechanism that causes renal phosphate wasting, with phosphate levels typically reaching a nadir in the first 1–2 weeks post-infusion and recovering gradually thereafter [14]. FCM is consistently associated with more hypophosphatemia than several other IV iron formulations, including ferric derisomaltose, a difference demonstrated in randomized comparisons [15].
In my experience, the fear of anaphylaxis often steals the spotlight in clinical settings. When no acute reaction occurs, there is a sense of reassurance that the infusion has been well tolerated. However, this focus on immediate safety can lead to delayed complications—such as hypophosphatemia—receiving less attention and going unrecognized in routine practice.
The clinical manifestations of significant hypophosphatemia include fatigue, proximal muscle weakness, bone pain, and in severe or prolonged cases, osteomalacia and fractures [15].
Iron overload. The human body has no effective mechanism for excreting excess iron. IV iron bypasses the intestinal regulatory system that normally limits absorption when stores are sufficient. In athletes who are not genuinely iron-deficient, or who receive IV iron repeatedly without appropriate monitoring, iron accumulation is a real risk. Finnish expert guidance explicitly warns that repeated IV iron on minimal indications can lead to harmful iron accumulation [7]. Excess iron is associated with oxidative stress and may contribute to tissue damage in cases of iron overload [9]. Monitoring of ferritin and transferrin saturation before and after IV iron treatment is essential.
Anti-doping regulations. Athletes competing under World Anti-Doping Agency (WADA) rules should be aware that IV infusions exceeding 100 mL within a 12-hour period are prohibited, unless received in the context of hospital admission, surgical procedures, or clinical diagnostic investigation [16]. Whether a specific infusion requires a Therapeutic Use Exemption depends on the treatment context — athletes should confirm their situation with their anti-doping organization in advance.
Infection risk. Any intravenous administration carries the inherent risk of infection at the access site. This risk is low in properly conducted clinical settings with aseptic technique, but it underscores why IV iron in non-clinical environments is not acceptable practice.
The most common infectious complication is a local infection at the cannulation site. While uncommon, these infections can, in rare cases, progress to systemic infection if not promptly recognized and treated. It is worth noting that this risk is not specific to IV iron, but applies to intravenous therapy more broadly, and in my experience, I encounter these complications from time to time in routine hospital practice.
Cost: A Practical Reality
IV iron is substantially more expensive than oral supplementation. Standard oral iron supplements cost only cents per dose. However, it is worth noting that some better-tolerated oral formulations, such as sucrosomial iron, are significantly more expensive—at least in Finland—although still typically less costly than IV therapy.
IV iron in clinical settings ranges from several hundred to several thousand euros depending on formulation and provider, with modern high-dose formulations among the most expensive per infusion [9]. To my current knowledge, in Finland, a 1,000 mg infusion of ferric carboxymaltose (Ferinject) in the private sector costs around €1,000 as of 2026, including both the medication and administration.
Finnish expert guidance is explicit that the cost of IV iron relative to oral therapy is difficult to justify for otherwise healthy individuals with isolated low ferritin and no anemia [7]. In the absence of a clear clinical indication, athletes funding IV iron privately should understand that higher cost does not necessarily translate into better or faster performance outcomes.
Conclusion
IV iron has a clear and important role in clinical practice—but only when used for the right indication. In athletes and patients alike, oral iron remains the first-line treatment in most cases, and many deficiencies can be effectively corrected without escalation to intravenous therapy.
While IV iron offers a faster route to restoring iron stores, its benefits are largely confined to those with true deficiency, particularly when anemia is present or oral therapy has genuinely failed. In patients without anemia, the performance and clinical benefits are inconsistent, and expectations often exceed measurable outcomes.
At the same time, IV iron is not without risk. Acute hypersensitivity reactions, delayed complications such as hypophosphatemia, and the potential for iron accumulation with repeated use all underscore that this is a medical intervention—not a benign shortcut.
In my experience, many patients are initially drawn to IV iron as a more powerful or immediate solution. However, over time, it becomes clear that it does not address the underlying cause of deficiency, and repeated treatments may be required if that cause is not managed. A more sustainable approach remains the combination of appropriate supplementation, dietary intake, and addressing the root cause of iron loss or impaired absorption.
Ultimately, the key question is not how quickly iron levels can be corrected, but whether the chosen treatment is appropriate, justified, and safe. IV iron, when used correctly, is a valuable tool. When used indiscriminately, it risks becoming an expensive and potentially harmful substitute for good clinical practice.
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10608302/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11863318/
- https://link.springer.com/article/10.1007/s40279-024-01992-8
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10939879/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4008387/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9949769/
- https://www.potilaanlaakarilehti.fi/artikkelit/raudanpuute-ilman-anemiaa-ndash-miten-ferritiiniarvoa-tulkitaan/
- https://pubmed.ncbi.nlm.nih.gov/23872938/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4678908/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9600424/
- https://pubmed.ncbi.nlm.nih.gov/25386711/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4172582/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6116100/
- https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14643
- https://pubmed.ncbi.nlm.nih.gov/39935027/
- https://www.wada-ama.org/sites/default/files/2023-10/tue_physician_guidelines_iv_infusion_october_2023.pdf
